World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
106
Citations
58733
World Ranking
6386
National Ranking
179

Overview

Kenneth J. O'Byrne is affiliated with Queensland University of Technology in Australia. Their research primarily focuses on fields such as Medicine and Biochemistry, Genetics and Molecular Biology, with significant contributions in Oncology, Pulmonary and Respiratory Medicine, and Molecular Biology. Their work integrates cross-disciplinary approaches within Cancer Research and Immunology subfields.

The scientist's research addresses topics including Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, Cancer Cells and Metastasis, DNA Repair Mechanisms, Immune cells in cancer, and Cancer Research and Treatments.

O'Byrne has published articles in frequent venues such as the Journal of Thoracic Oncology, Journal of Clinical Oncology, Annals of Oncology, Cancer Research, and Lung Cancer.

Recent papers by Kenneth J. O'Byrne include:

  • Immune Checkpoint Inhibitors in Cancer Therapy, 2022, Current Oncology
  • PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance, 2020, Frontiers in Cell and Developmental Biology
  • Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227, 2022, Journal of Clinical Oncology
  • First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial, 2021, Journal of Thoracic Oncology
  • Understanding the tumor microenvironment for effective immunotherapy, 2020, Medicinal Research Reviews

They regularly collaborate with coauthors including Arutha Kulasinghe, James Monkman, Derek J. Richard, Rahul Ladwa, and Mark N. Adams.

Best Publications

  • Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

    Alice T. Shaw;Dong Wan Kim;Kazuhiko Nakagawa;Takashi Seto

  • Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

    Lecia V. Sequist;James Chih-Hsin Yang;Nobuyuki Yamamoto;Kenneth John O'Byrne

  • Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

    Matthew D. Hellmann;Tudor-Eliade Ciuleanu;Adam Pluzanski;Jong Seok Lee

  • Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

    Matthew D Hellmann;Luis Paz-Ares;Reyes Bernabe Caro;Bogdan Zurawski

  • Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group

    Michael Marty;Francesco Cognetti;Dominique Maraninchi;Raymond Snyder

  • Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

    Robert Pirker;Jose R. Pereira;Aleksandra Szczesna;Joachim von Pawel

  • Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

    James Chih Hsin Yang;Yi Long Wu;Martin Schuler;Martin Sebastian

  • Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

    Keunchil Park;Eng Huat Tan;Ken O'Byrne;Li Zhang

  • EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

    Robert Pirker;Jose R. Pereira;Joachim Von Pawel;Maciej Krzakowski

  • Chronic immune activation and inflammation as the cause of malignancy.

    Kenneth J. O'Byrne;A. G. Dalgleish

  • Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I Studies

    Bruno Morgan;Anne L. Thomas;Joachim Drevs;Juergen Hennig

  • Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

    Amila Suraweera;Kenneth J. O’Byrne;Kenneth J. O’Byrne;Derek J. Richard

  • Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study

    Tom Treasure;Loic Lang-Lazdunski;David Waller;Judith M Bliss

  • 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

    J. Vansteenkiste;L. Crinò;C. Dooms;J. Y. Douillard

  • First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.

    Neal Ready;Matthew D. Hellmann;Mark M. Awad;Gregory A. Otterson

  • Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.

    L. Paz-Ares;E. H. Tan;K. O'Byrne;L. Zhang

  • PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance.

    Maddison Rose;Joshua T. Burgess;Kenneth O’Byrne;Kenneth O’Byrne;Derek J. Richard

  • 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer

    W.E.E. Eberhardt;D. De Ruysscher;W. Weder;C. Le Péchoux

  • Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems

    J G Edwards;K R Abrams;J N Leverment;T J Spyt

  • Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer

    T.S. Mok;Y.-L. Wu;M.-J. Ahn;M.C. Garassino

Frequent Co-Authors

Tony Mok
Tony Mok Chinese University of Hong Kong
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid
William P. Steward
William P. Steward University of Leicester
Michael Boyer
Michael Boyer University of Utah
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Lecia V. Sequist
Lecia V. Sequist Harvard University
John V. Reynolds
John V. Reynolds Trinity College Dublin
Suresh S. Ramalingam
Suresh S. Ramalingam Emory University
Majid Ebrahimi Warkiani
Majid Ebrahimi Warkiani University of Technology Sydney
Yi-Long Wu
Yi-Long Wu Guangdong Provincial People’s Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering studying Medicine in the USA, there are many related online degree options and career paths worth exploring. Pursuing a health administration degree is an excellent way to build foundational skills in leadership, budgeting, and healthcare systems—all highly valued in today’s medical field.

For those seeking advanced roles, understanding the cost of MHA degree programs can help you plan your investment in a master’s-level healthcare administration career. Similarly, doctoral-level credentials can expand your opportunities, especially with the growing demand for nursing leaders. Considering the cheapest DNP program options ensures you can advance in nursing without undue financial burden.

Pharmacists are also in demand, and online Pharm D online programs allow for greater flexibility and affordability. Exploring these alternative and complementary career pathways can help you reach your healthcare goals, maintain work-life balance, and manage educational costs effectively.

Best Scientists Citing Kenneth J. O'Byrne

Trending Scientists

Recently Published Articles